title: The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs.
authors: Department of Dermatology, Frankfurt University Medical School, Germany. Boehmcke@em.uni-frankfurt.de
authors: W H
authors: WH
authors: Boehncke
authors: M
authors: M
authors: Kock
authors: K
authors: K
authors: Hardt-Weinelt
authors: M
authors: M
authors: Wolter
authors: R
authors: R
authors: Kaufmann
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011804:Quinolines / Q000627:therapeutic use; D016038:Skin Transplantation
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011804:Quinolines; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; D003907:Dexamethasone